Lates News

Shanghai Pharmaceuticals announced that the aripiprazole tablets produced by its subsidiary, Shanghai Shang Yao Traditional Chinese Medicine Company Limited, have received a drug registration certificate issued by the Food and Drug Administration of the Philippines, allowing the medication to be approved for sale. Aripiprazole tablets are an antipsychotic medication mainly used to treat schizophrenia and manic episodes in bipolar disorder, and can also be used as an adjunctive therapy for depression. The company has invested approximately 50,000 RMB in registration fees for the listing in the Philippines. The total sales revenue for aripiprazole tablets (10 mg) in the Philippines market in 2024 was 2.39 million US dollars.